Epidermal growth factor receptor inhibitors: A new era of drug reactions in a new era of cancer therapy

Journal of the American Academy of Dermatology

Volumn 56, Issue 3, 2007, Pages 514-517

  Cowen, Edward W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOYL PEROXIDE; BETAMETHASONE; CETUXIMAB; CLOBETASOL PROPIONATE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ERYTHROMYCIN; FLUOROPYRIMIDINE; FUSIDIC ACID; GEFITINIB; HEXAMIDINE; IRINOTECAN; ISOTRETINOIN; ITRACONAZOLE; METRONIDAZOLE; OXALIPLATIN; PANITUMUMAB; POVIDONE IODINE; RETINOID; SORAFENIB; SUNITINIB; TETRACYCLINE DERIVATIVE;

ABSCESS; ALOPECIA; CANCER THERAPY; COLORECTAL CANCER; DRY SKIN; EDITORIAL; FACE ERYTHEMA; FOLLICULITIS; HAIR DISEASE; HAND FOOT SYNDROME; HUMAN; KERATOACANTHOMA; PARONYCHIA; PRIORITY JOURNAL; PRURITUS; PYOGENIC GRANULOMA; RASH; SEPSIS; SIDE EFFECT; SKIN FISSURE; SKIN PIGMENTATION; SKIN TOXICITY; XEROSIS;

ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; HUMANS; ISOTRETINOIN; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33847075418     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.11.004     Document Type: Editorial

References (30)

1. National Cancer Institute Cancer Therapy Evaluation Program Common Toxicity Criteria for Adverse Events v3.0 [homepage on the Internet]. Bethesda (MD). Available at: http://ctep.cancer.gov/reporting/ctc_v30.html. Accessed October 24, 2006.
2. Amgen [homepage on the Internet]. Thousand Oaks (Calif); c.2000-5. Available at: http://wwwext.amgen.com/pdfs/products/vectibix_pi.pdf. Accessed October 24, 2006.
3. Hochster H.S., Haller D.G., de Gramont A., Berlin J.D., Philip P.A., Moore M.J., et al. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer 107 (2006) 676-685
4. Astsaturov I., Cohen R.B., and Harari P. Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer. Expert Rev Anticancer Ther 6 (2006) 1179-1193
5. Baselga J., and Cortes J. Epidermal growth factor receptor pathway inhibitors. Cancer Chemother Biol Response Modif 22 (2005) 205-223
6. Xiong H.Q., Rosenberg A., LoBuglio A., Schmidt W., Wolff R.A., Deutsch J., et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 22 (2004) 2610-2616
7. Green M.R., and Couchman J.R. Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition. J Invest Dermatol 85 (1985) 239-245
8. Nanney L.B., Magid M., Stoscheck C.M., and King Jr. L.E. Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol 83 (1984) 385-393
9. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5 (2005) 341-354
10. Baselga J. Skin as a surrogate tissue for pharmacodynamic end points: is it deep enough?. Clin Cancer Res 9 (2003) 2389-2390
11. Lenz H.J. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology 20 5 Suppl 2 (2006) 5-13
12. Bristol-Myers Squibb [homepage on the Internet]. New York; c1999-2006. Available from: =http://www.erbitux.com/erbitux/home/portal.jsp?BV_UseBVCookie=Yes. Accessed October 24, 2006.
13. Green M.R., Basketter D.A., Couchman J.R., and Rees D.A. Distribution and number of epidermal growth factor receptors in skin is related to epithelial cell growth. Dev Biol 100 (1983) 506-512
14. Jost M., Kari C., and Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 10 (2000) 505-510
15. Busam K.J., Capodieci P., Motzer R., Kiehn T., Phelan D., and Halpern A.C. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144 (2001) 1169-1176
16. Van Doorn R., Kirtschig G., Scheffer E., Stoof T.J., and Giaccone G. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 147 (2002) 598-601
17. Agero A.L., Dusza S.W., Benvenuto-Andrade C., Busam K.J., Myskowski P., and Halpern A.C. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55 (2006) 657-670
18. Roe E., Garcia Muret M.P., Marcuello E., Capdevila J., Pallares C., and Alomar A. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 55 (2006) 429-437
19. Segaert S., Tabernero J., Chosidow O., Dirschka T., Elsner J., Mancini L., et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 3 (2005) 599-606
20. Robert C., Soria J.C., Spatz A., Le Cesne A., Malka D., Pautier P., et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6 (2005) 491-500
21. Matheis P., Socinski M.A., Burkhart C., Warren S., and Thomas N.E. Treatment of gefitinib-associated folliculitis. J Am Acad Dermatol 55 (2006) 710-713
22. Jacot W., Bessis D., Jorda E., Ychou M., Fabbro M., Pujol J.L., et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 151 (2004) 238-241
23. DeWitt C.A., Siroy A.E., and Stone S.P. Acneiform eruptions associated with epidermal growth factor targeted chemotherapy. J Am Acad Dermatol 56 (2007) 500-505
24. Cuetara M.S., Aguilar A., Martin L., Aspiroz C., and del Palacio A. Erlotinib associated with rosacea-like folliculitis and Malassezia sympodialis. Br J Dermatol 155 (2006) 477-479
25. Herbst R.S., Maddox A.M., Rothenberg M.L., Small E.J., Rubin E.H., Baselga J., et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 20 (2002) 3815-3825
26. Perez-Soler R., Delord J.P., Halpern A., Kelly K., Krueger J., Sureda B.M., et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10 (2005) 345-356
27. Gutzmer R., Werfel T., Mao R., Kapp A., and Elsner J. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 153 (2005) 849-851
28. Graves J.E., Jones B.F., Lind A.C., and Heffernan M.P. Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. J Am Acad Dermatol 55 (2006) 349-353
29. Shu K.Y., Kindler H.L., Medenica M., and Lacouture M. Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br J Dermatol 154 (2006) 191-192
30. Crombet T., Osorio M., Cruz T., Roca C., del Castillo R., Mon R., et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 22 (2004) 1646-1654